HAYWARD, Calif.--(

加利福尼亚州海沃德--(

BUSINESS WIRE

商业热线

)--Rondo Therapeutics, a privately held biopharmaceutical immuno-oncology company pioneering the development of next-generation T cell-engaging bispecific antibodies for the treatment of solid tumors, today announced that data from preclinical studies of RNDO-564, a novel CD28 x Nectin-4 costimulatory bispecific antibody for advanced bladder cancer, is being presented in a poster session at the 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place February 13-15, 2025, in San Francisco, CA..

)--Rondo Therapeutics是一家私营生物制药免疫肿瘤学公司，率先开发用于治疗实体瘤的下一代T细胞双特异性抗体，今天宣布，RNDO-564（一种新型CD28 x Nectin-4共刺激双特异性抗体）的临床前研究数据正在2025年2月13日至15日在加利福尼亚州旧金山举行的2025年美国临床肿瘤学会（ASCO）泌尿生殖系统（GU）癌症研讨会的海报上发布。。

“CD28 co-stimulatory bispecific antibodies are designed to boost T cell-mediated tumor killing and overcome T cell exhaustion in the solid tumor microenvironment. In preclinical studies, RNDO-564 demonstrated robust anti-tumor activity in vivo and in vitro, including in an antibody drug conjugate (ADC)-resistant bladder cancer model, suggesting the ability of RNDO-564 to overcome T cell exhaustion and address limitations of ADCs, including toxicity, resistance, and sequential ADC re-challenge,” said Thomas Manley, CMO of Rondo Therapeutics.

。

“Based on these promising preclinical findings, we are advancing RNDO-564 through IND-enabling studies, with the goal of entering the clinic in advanced bladder cancer by year-end.”.

“基于这些有希望的临床前研究结果，我们正在通过IND使能研究推进RNDO-564，目标是在年底前进入晚期膀胱癌临床。”。

Key Findings

主要调查结果

RNDO-564 is designed to elicit robust Nectin-4 and signal-1 dependent T-cell mediated killing of Nectin-4-expressing tumor cells

RNDO-564被设计用于引发强大的Nectin-4和信号依赖性T细胞介导的Nectin-4表达肿瘤细胞的杀伤

RNDO-564 restored tumor cell killing function of serially stimulated T cells in vitro

RNDO-564 inhibited tumors in vivo as monotherapy and in combination with checkpoint therapy in vivo

RNDO-564作为单一疗法在体内抑制肿瘤，并与体内检查点疗法联合使用

Preliminary toxicology studies support clinical evaluation of RNDO-564

初步毒理学研究支持RNDO-564的临床评估

RNDO-564 maintained cytotoxicity against antibody drug conjugate-resistant bladder cancer cells

RNDO-564对抗体-药物偶联物耐药的膀胱癌细胞具有细胞毒性

Poster Session Details

海报会话详细信息

Title:

标题：

A novel CD28 x Nectin-4 costimulatory bispecific antibody for advanced bladder cancer

新型CD28 x Nectin-4共刺激双特异性抗体治疗晚期膀胱癌

Poster No.:

海报编号：

810

810

Session:

会议：

Poster Session B: Urothelial Carcinoma

海报会议B：尿路上皮癌

Date/Time:

日期/时间：

Friday, February 14, 2025 = 11:30am-12:45pm PST

2025年2月14日星期五=太平洋标准时间上午11:30-下午12:45

Rondo Therapeutics’ proprietary platform features CD28-targeting binders with a wide range of co-stimulatory potencies designed to boost T cell-mediated tumor killing and overcome T cell exhaustion in the solid tumor microenvironment. Rondo’s platform delivers bispecific antibody therapeutics tailored to specific tumor targets, indications, and treatment regimens, offering a transformative alternative to traditional “one size fits all” strategies, unlocking the potential for durable responses in patients with solid tumors..

。Rondo的平台提供了针对特定肿瘤靶标，适应症和治疗方案量身定制的双特异性抗体治疗剂，为传统的“一刀切”策略提供了一种变革性的替代方案，释放了实体瘤患者持久反应的潜力。。

About Rondo Therapeutics:

关于Rondo Therapeutics：

Rondo Therapeutics is a biopharmaceutical company breaking new ground in cancer therapy. The company’s mission is to advance bispecific antibody therapies that address unmet needs in the treatment of solid tumors. Rondo is developing a new class of bispecific antibodies designed to harness the immune system to target and eliminate tumors with enhanced safety.

Rondo Therapeutics是一家在癌症治疗领域开创新局面的生物制药公司。该公司的使命是推进双特异性抗体疗法，以解决实体瘤治疗中未满足的需求。Rondo正在开发一类新的双特异性抗体，旨在利用免疫系统以增强安全性的方式靶向和消除肿瘤。

Rondo Therapeutics is supported by Canaan Partners, Red Tree Venture Capital, Johnson & Johnson, SV Health Investors, and Novo Holdings. The company’s pipeline includes immune-engaging bispecifics for a range of solid tumors, including bladder and ovarian cancers. For more information, please visit .

Rondo Therapeutics得到了Canaan Partners，Red Tree Venture Capital，Johnson＆Johnson，SV Health Investors和Novo Holdings的支持。该公司的产品线包括针对一系列实体瘤（包括膀胱癌和卵巢癌）的免疫双特异性药物。有关更多信息，请访问。

www.rondotx.com

www.rondotx.com

.

.